Are you unsure whether Fragment Based Drug Discovery is a valid approach for your target?

Fragment Based Drug Discovery is now a well-established method to develop small molecule therapeutics for challenging drug targets. Orthosteric inhibitors, allosteric inhibitors (Asciminib) and Molecular Glues (ImIDs) are just some of the mechanisms of action exhibited by fragment derived compounds. Venetoclax, which targets a protein-protein interaction, is the most well-known marketed drug derived from FBDD. However, many drug hunters are still not comfortable with FBDD or are uncertain whether it is the best approach for their target.

Now ZoBio has introduced a low hurdle approach to help solve these issues. In less than 3 months, we will produce a high quality sample of your target appropriately tagged for immobilization with retention of biological activity. We will then setup an SPR assay capable of reliably detecting fragment binding and use it to screen the 151 member pilot plate from our proprietary fragment library. Hits from this screen will be titrated and we will deliver a data package that includes the number of chemotypes in the confirmed hit list and the affinity with which they bind your target, where we can determine it. Finally, these results will be benchmarked against our more than 120 previous fragment campaigns to provide guidance on the ligandability of your target.

Using the data from this short, but quality study, in combination with our decades of experience, a well-informed decision can be made whether or not FBDD is an expeditious approach for your target. Your risk is further reduced through a fixed price for the package.